Associate Scientist I/II: Biomolecular Interaction Characterization
Dragonfly Therapeutics is seeking a highly motivated and talented Associate Scientist I/II to be a valuable member of the Protein Analytics group, title commensurate with experience. In this role you, will contribute to the development of next-generation biologics including multispecific antibodies, cytokine-fusions, and novel agents for the treatment of cancer, autoimmune disease, neuro-inflammation, and beyond. The successful candidate will perform detailed biomolecular interaction analyses to determine kinetic rates, affinities, epitope bins, and other critical binding properties using state of the art biosensing technologies.
Responsibilities (including but not limited to):
- Design and execute biomolecular interaction experiments with recombinant, membrane-stabilized, and cell expressed proteins using Surface Plasmon Resonance (SPR) and Kinetic Exclusion Assay (KinExA) platforms
- Characterize recombinant proteins by SEC-MALS, SDS-PAGE, and intact mass analysis
- Purify recombinant proteins on an ÄKTA Pure FPLC using affinity, ion exchange, and size exclusion chromatography
- Perform cell culture on mammalian cells expressing desired protein targets
- Document observations and data in detailed electronic lab notebooks
- Analyze and present data at group meetings
Qualifications:
- BS/MS with 1+ year relevant industrial experience in biotherapeutic characterization and development
- Experience with Biacore 8K, Carterra LSA, and KinExA 4000 instruments preferred
- Knowledge of protein chemistry and antibody sciences is desirable
- Excellent verbal and written communication skills
About Dragonfly
Dragonfly Therapeutics is a clinical-stage biopharmaceutical company committed to discovering, developing and commercializing therapies that use its novel multispecific antibody technology to harness the body's immune system to bring breakthrough treatments to patients. In addition to its wholly owned clinical assets, Dragonfly has a deep pipeline of wholly owned preclinical candidates discovered using its proprietary platform, as well as productive collaborations with Merck, AbbVie, Gilead and Bristol Myers Squibb in a broad range of disease areas.
Our mission is to revolutionize disease treatment by inventing natural killer cell-based therapies for vastly improved patient outcomes. We believe in a small team with a big impact.
Top Skills
What We Do
Dragonfly Therapeutics is a clinical-stage biotech developing novel first-in-class therapeutics targeted at natural killer cells and other cells of the innate immune system. These therapies are designed to counterbalance immune suppressive factors present in the tumor microenvironment and mobilize anti-cancer immune responses. Our molecules are expected to be potent as single agents as well as in treatment combinations with existing cancer immunotherapies. Our scientific founders are major figures in cancer biology and immunology and have launched Dragonfly to harness the power of the immune system to provide breakthrough cancer treatments for patients. For more information, email [email protected].
